Alvotech (ALVO) said Monday the European Commission has approved its denosumab biosimilar medicine used to treat osteoporosis and help prevent serious bone problems in some forms of cancer.

In Europe, Alvotech will supply the medicine to partners Stada and Dr Reddy's (RDY), which will sell it under the brands Kefdensis, Zvogra, Acvybra, and Xbonzy, while Prolia and Xgeva remain registered trademarks of Amgen (AMGN), the company said.

The drug is a biosimilar to denosumab, and the European market for this treatment is worth about $1.2 billion a year across its approved uses, the company said.

It is cleared in one form for treating osteoporosis and bone loss and in another for preventing serious bone complications in adults with advanced cancer that has spread to bone, it said.